The pathogenesis and treatment of no-reflow occurring during percutaneous coronary intervention

Mohammad R Movahed, Samuel M. Butman

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

No-reflow is one of the major causes of postinterventional rise of cardiac enzyme and myocardial infarction (MI). This complication is associated with substantial morbidity and mortality after percutaneous coronary intervention (PCI). During and after a no-reflow episode, the patient can suffer from severe chest pain, hypotension, bradycardia, hemodynamic collapse, MI, congestive heart failure, and death. Every effort should be taken to reduce the incidence of this complication. The distal embolic protection device has been shown to decrease this risk in saphenous vein graft (SVG) interventions but not in native coronaries. On the other hand, the use of glycoprotein IIb/IIIa receptor antagonists have been effective in reducing the occurrence of no-reflow during PCI of native coronaries but not during SVG interventions. The treatment of no-reflow is based on the intracoronary administrations of medications that induce maximal vasodilatation in small distal coronary vasculature. The most commonly used drugs in this setting are adenosine, nitroprusside, and verapamil. The goal of this study was to review the pathogenesis and treatment of no-reflow in patients undergoing PCI.

Original languageEnglish (US)
Pages (from-to)56-61
Number of pages6
JournalCardiovascular Revascularization Medicine
Volume9
Issue number1
DOIs
StatePublished - Jan 2008

Fingerprint

Percutaneous Coronary Intervention
Saphenous Vein
Embolic Protection Devices
Myocardial Infarction
Transplants
Platelet Glycoprotein GPIIb-IIIa Complex
Nitroprusside
Bradycardia
Verapamil
Chest Pain
Vasodilation
Adenosine
Hypotension
Therapeutics
Heart Failure
Hemodynamics
Morbidity
Mortality
Incidence
Enzymes

Keywords

  • Balloon angioplasty
  • Complications
  • No-reflow
  • PCI
  • Percutaneous coronary intervention
  • PTCA
  • Stenting

ASJC Scopus subject areas

  • Molecular Medicine
  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

The pathogenesis and treatment of no-reflow occurring during percutaneous coronary intervention. / Movahed, Mohammad R; Butman, Samuel M.

In: Cardiovascular Revascularization Medicine, Vol. 9, No. 1, 01.2008, p. 56-61.

Research output: Contribution to journalArticle

@article{a71fe90e6bc0443bbc84f18002b5bf21,
title = "The pathogenesis and treatment of no-reflow occurring during percutaneous coronary intervention",
abstract = "No-reflow is one of the major causes of postinterventional rise of cardiac enzyme and myocardial infarction (MI). This complication is associated with substantial morbidity and mortality after percutaneous coronary intervention (PCI). During and after a no-reflow episode, the patient can suffer from severe chest pain, hypotension, bradycardia, hemodynamic collapse, MI, congestive heart failure, and death. Every effort should be taken to reduce the incidence of this complication. The distal embolic protection device has been shown to decrease this risk in saphenous vein graft (SVG) interventions but not in native coronaries. On the other hand, the use of glycoprotein IIb/IIIa receptor antagonists have been effective in reducing the occurrence of no-reflow during PCI of native coronaries but not during SVG interventions. The treatment of no-reflow is based on the intracoronary administrations of medications that induce maximal vasodilatation in small distal coronary vasculature. The most commonly used drugs in this setting are adenosine, nitroprusside, and verapamil. The goal of this study was to review the pathogenesis and treatment of no-reflow in patients undergoing PCI.",
keywords = "Balloon angioplasty, Complications, No-reflow, PCI, Percutaneous coronary intervention, PTCA, Stenting",
author = "Movahed, {Mohammad R} and Butman, {Samuel M.}",
year = "2008",
month = "1",
doi = "10.1016/j.carrev.2007.08.005",
language = "English (US)",
volume = "9",
pages = "56--61",
journal = "Cardiovascular Revascularization Medicine",
issn = "1553-8389",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - The pathogenesis and treatment of no-reflow occurring during percutaneous coronary intervention

AU - Movahed, Mohammad R

AU - Butman, Samuel M.

PY - 2008/1

Y1 - 2008/1

N2 - No-reflow is one of the major causes of postinterventional rise of cardiac enzyme and myocardial infarction (MI). This complication is associated with substantial morbidity and mortality after percutaneous coronary intervention (PCI). During and after a no-reflow episode, the patient can suffer from severe chest pain, hypotension, bradycardia, hemodynamic collapse, MI, congestive heart failure, and death. Every effort should be taken to reduce the incidence of this complication. The distal embolic protection device has been shown to decrease this risk in saphenous vein graft (SVG) interventions but not in native coronaries. On the other hand, the use of glycoprotein IIb/IIIa receptor antagonists have been effective in reducing the occurrence of no-reflow during PCI of native coronaries but not during SVG interventions. The treatment of no-reflow is based on the intracoronary administrations of medications that induce maximal vasodilatation in small distal coronary vasculature. The most commonly used drugs in this setting are adenosine, nitroprusside, and verapamil. The goal of this study was to review the pathogenesis and treatment of no-reflow in patients undergoing PCI.

AB - No-reflow is one of the major causes of postinterventional rise of cardiac enzyme and myocardial infarction (MI). This complication is associated with substantial morbidity and mortality after percutaneous coronary intervention (PCI). During and after a no-reflow episode, the patient can suffer from severe chest pain, hypotension, bradycardia, hemodynamic collapse, MI, congestive heart failure, and death. Every effort should be taken to reduce the incidence of this complication. The distal embolic protection device has been shown to decrease this risk in saphenous vein graft (SVG) interventions but not in native coronaries. On the other hand, the use of glycoprotein IIb/IIIa receptor antagonists have been effective in reducing the occurrence of no-reflow during PCI of native coronaries but not during SVG interventions. The treatment of no-reflow is based on the intracoronary administrations of medications that induce maximal vasodilatation in small distal coronary vasculature. The most commonly used drugs in this setting are adenosine, nitroprusside, and verapamil. The goal of this study was to review the pathogenesis and treatment of no-reflow in patients undergoing PCI.

KW - Balloon angioplasty

KW - Complications

KW - No-reflow

KW - PCI

KW - Percutaneous coronary intervention

KW - PTCA

KW - Stenting

UR - http://www.scopus.com/inward/record.url?scp=38149113860&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38149113860&partnerID=8YFLogxK

U2 - 10.1016/j.carrev.2007.08.005

DO - 10.1016/j.carrev.2007.08.005

M3 - Article

C2 - 18206640

AN - SCOPUS:38149113860

VL - 9

SP - 56

EP - 61

JO - Cardiovascular Revascularization Medicine

JF - Cardiovascular Revascularization Medicine

SN - 1553-8389

IS - 1

ER -